Protein

Protein Sciences is a biotechnology company specializing in the development and manufacturing of recombinant vaccines and biopharmaceuticals. The company is best known for developing Flublok, the first recombinant protein-based influenza vaccine approved by the FDA, which utilizes a proprietary baculovirus expression system. This technology allows for the rapid production of high-quality proteins without the need for live virus or eggs, making it a critical platform for pandemic preparedness. In 2017, the company was acquired by Sanofi to bolster its global influenza vaccine portfolio and expand its capabilities in recombinant technology.